Concepedia

Rosario Arechavaleta

RA

Statistics

Publications

3

Citations

312

H-Index

3

Active since

2010

Affiliations

Universidad Autónoma de Guadalajara(Current)

Novo Nordisk (Denmark)

Swansea University

LMC Diabetes & Endocrinology (Canada)

Rosario Arechavaleta is an author at Universidad Autónoma de Guadalajara specializing in clinical pharmacology, pharmacology, and diabetes pharmacotherapy.

Publications per year

2010–2025

3

Publications

3

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial

Rosario Arechavaleta, Thomas Seck, Karl J. Krobot et al. · Diabetes Obesity and Metabolism · 2010 · 164 citations

, , +17

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Stephen C. Bain, Ofri Mosenzon, Rosario Arechavaleta et al. · Diabetes Obesity and Metabolism · 2018 · 97 citations · Full text

, , +17

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

Nikolaus Marx, John Deanfield, Johannes F.E. Mann et al. · Circulation · 2025 · 51 citations · Full text

, , +17

1–3 of 3